Your browser doesn't support javascript.
loading
Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.
Taibi, Abdelkader; Sgarbura, Olivia; Hübner, Martin; Bardet, Sylvia M; Alyami, Mohammed; Bakrin, Naoual; Durand Fontanier, Sylvaine; Eveno, Clarisse; Gagniere, Johan; Pache, Basile; Pocard, Marc; Quenet, François; Teixeira Farinha, Hugo; Thibaudeau, Emilie; Dumont, Frederic; Glehen, Olivier.
Afiliación
  • Taibi A; Digestive Surgery Department, Dupuytren Limoges University Hospital, Limoges, France. abdelkader.taibi@hotmail.Fr.
  • Sgarbura O; CNRS, XLIM, UMR 7252, University Limoges, Limoges, France. abdelkader.taibi@hotmail.Fr.
  • Hübner M; Department of Surgical Oncology, Cancer Institute Montpellier (ICM), University of Montpellier, Montpellier, France.
  • Bardet SM; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France.
  • Alyami M; Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.
  • Bakrin N; CNRS, XLIM, UMR 7252, University Limoges, Limoges, France.
  • Durand Fontanier S; Department of General Surgery and Surgical Oncology, Lyon Sud University Hospital, Pierre Benite, France.
  • Eveno C; Department of General Surgery and Surgical Oncology, King Khalid Hospital, Najran, Saudi Arabia.
  • Gagniere J; Department of General Surgery and Surgical Oncology, Lyon Sud University Hospital, Pierre Benite, France.
  • Pache B; Digestive Surgery Department, Dupuytren Limoges University Hospital, Limoges, France.
  • Pocard M; CNRS, XLIM, UMR 7252, University Limoges, Limoges, France.
  • Quenet F; Department of General Surgery, University Hospital Lille, Lille, France.
  • Teixeira Farinha H; Department of General Surgery, University Hospital Clermont-Ferrand, Clermont-Ferrand, France.
  • Thibaudeau E; Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.
  • Dumont F; INSERM U1275, CAP Paris-Tech, Carcinomatosis Peritoneum Paris Technology, Lariboisière Hospital, AP-HP, Paris 7 -Diderot University, Sorbonne Paris Cité, Paris, France.
  • Glehen O; Hepato-Biliary-Pancreatic Gastrointestinal Surgery and Liver Transplantation Pitié-Salpêtrière Hospital Assistance Publique/Hôpitaux de Paris, 75013, Paris, France.
Ann Surg Oncol ; 29(8): 5243-5251, 2022 Aug.
Article en En | MEDLINE | ID: mdl-35318519
BACKGROUND: This retrospective multicenter cohort study compared the feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-Ox) with or without intraoperative intravenous 5-fluorouracil (5-FU) and leucovorin (L). METHODS: Our study included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM) treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox + 5-FU/L group) and patients who did not (PIPAC-Ox group). RESULTS: In total, 101 patients (263 procedures) were included in the PIPAC-Ox group and 30 patients (80 procedures) were included in the PIPAC-Ox + 5-FU/L group. Common Terminology Criteria for Adverse Events v4.0 grade 2 or higher adverse events occurred in 48 of 101 (47.5%) patients in the PIPAC-Ox group and in 13 of 30 (43.3%) patients in the PIPAC-Ox + 5-FU/L group (p = 0.73). The complete histological response rates according to the peritoneal regression grading score were 27% for the PIPAC-Ox + 5-FU/L group and 18% for the PIPAC-Ox group (p = 0.74). No statistically significant differences were observed in overall or progression-free survival between the two groups. CONCLUSIONS: The safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Neoplasias Colorrectales Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Neoplasias Colorrectales Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos